Association between interleukin-6 and head and neck squamous cell carcinoma: A systematic review

Creative Commons License

Uz U., ESKİİZMİR G.

Clinical and Experimental Otorhinolaryngology, vol.14, no.1, pp.50-60, 2021 (SCI-Expanded, Scopus) identifier identifier

  • Publication Type: Article / Review
  • Volume: 14 Issue: 1
  • Publication Date: 2021
  • Doi Number: 10.21053/ceo.2019.00906
  • Journal Name: Clinical and Experimental Otorhinolaryngology
  • Journal Indexes: Science Citation Index Expanded (SCI-EXPANDED), Scopus, Directory of Open Access Journals
  • Page Numbers: pp.50-60
  • Keywords: Carcinogenesis, Head and Neck Neoplasms, Inflammation, Interleukin 6, Survival
  • Open Archive Collection: AVESIS Open Access Collection
  • Manisa Celal Bayar University Affiliated: Yes

Abstract

Interleukin-6 (IL-6) is a proinflammatory cytokine which plays an important role in several regulatory mechanisms of can-cer. Moreover, experimental and clinical studies have reported that IL-6 targeted therapies might provide significant bene-fits for cancer treatment. The purpose of this systematic review is to evaluate IL-6 activity in patients with head and neck squamous cell carcinoma (HNSCC). A systematic review of the association between serum, saliva and tumor IL-6 and HN-SCC was developed on PubMed/Medline in the publication range from January 1995 to January 2019. Our literature analysis demonstrated that overexpression and elevated serum and/or saliva IL-6 concentrations in patients with HNSCC are related to poor survival and oncological outcomes. Although there is a correlation between IL-6 concentrations and tumor-igenicity, it is noteworthy that IL-6 targeted therapies are generally performed in vitro and in experimental studies. There-fore, prospective, randomized clinical trials are required that focus on IL-6 targeted therapies for the treatment of HNSCC.